Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) announced promising preclinical findings for KT-474, an oral IRAK4 degrader, showing its superior anti-inflammatory effects compared to existing IRAK4 kinase inhibitors. This late-breaking data, highlighted at the IMMUNOLOGY2021 conference, demonstrates KT-474's efficacy in various models of immune-inflammatory diseases, including atopic dermatitis and rheumatoid arthritis. With a broader mechanism targeting both kinase and scaffolding functions of IRAK4, KT-474 aims to address significant unmet medical needs. Further clinical validation is anticipated in upcoming trials.
Kymera Therapeutics (NASDAQ: KYMR) reported strong business highlights for Q1 2021, with collaboration revenues soaring to $18.7 million, up from $3.4 million in Q1 2020. The company initiated a Phase 1 trial for its oral IRAK4 degrader, KT-474, in February 2021, targeting immune-inflammatory diseases. Expected milestones include proof-of-biology data for KT-474 in 4Q 2021. Additionally, preclinical programs KT-413 and KT-333 are advancing towards clinical trials in 2H 2021. Despite a net loss of $13.1 million, Kymera has sufficient cash to fund operations into 2025.
Kymera Therapeutics (NASDAQ: KYMR) appointed Juliet Williams, PhD, as Senior Vice President, Head of Biology. Dr. Williams brings 20 years of experience in the biopharmaceutical sector, including drug discovery leadership roles at Novartis and Sanofi. Her expertise is expected to enhance Kymera's pipeline, including programs in immunology and oncology. This strategic hire is poised to bolster Kymera's efforts in developing targeted protein degradation therapies aimed at treating challenging diseases.
Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in two upcoming investor conferences. The company will present at the BofA Securities 2021 Virtual Healthcare Conference on May 13 at 3:30 p.m. ET and at the UBS Global Healthcare Virtual Conference on May 25 at 12:00 p.m. ET. Live webcasts will be available on Kymera's website, with archived replays for 30 days. Kymera focuses on targeted protein degradation to address challenging disease targets using its Pegasus™ platform, aiming to develop new treatments for various immune-inflammatory diseases and cancers.
Kymera Therapeutics (NASDAQ: KYMR) announced new preclinical data for its IRAK4 degrader KT-474 at the IMMUNOLOGY2021™ annual meeting. The data show KT-474's superior anti-inflammatory activity over existing IRAK4 inhibitors in various models. The presentation will occur on May 13, 2021, highlighting its impact on conditions like atopic dermatitis and rheumatoid arthritis. The company initiated a Phase 1 trial in February to assess KT-474's safety and efficacy, indicating its potential as a first-in-class therapy.
Kymera Therapeutics (KYMR) presented positive data at the 2021 Society for Investigative Dermatology Annual Meeting regarding its IRAK4 degrader, KT-474. The non-interventional study involved 30 hidradenitis suppurativa (HS) patients, revealing significant IRAK4 protein overexpression in HS skin lesions compared to healthy subjects. KT-474 demonstrated the ability to inhibit inflammatory gene upregulation in treated monocytes. The findings support KT-474's potential therapeutic impact on HS, a chronic inflammatory disease with unmet medical needs. Future data is anticipated from ongoing studies.
Kymera Therapeutics (NASDAQ: KYMR) has been recognized by the Boston Business Journal as one of the 2021 Best Places to Work in Massachusetts. This accolade reflects the company’s commitment to fostering a positive work culture focused on transparency, inclusion, and innovation. Kymera aims to advance targeted protein degradation therapies to address challenging disease targets. Their platform, Pegasus™, focuses on degrading disease-causing proteins, targeting previously inaccessible pathways. The recognition underscores Kymera's ambition to enhance its organizational capabilities as it progresses in the biopharmaceutical sector.
Kymera Therapeutics (NASDAQ: KYMR) recently unveiled preclinical data demonstrating the effectiveness of KT-413, a dual-action IRAKIMiD degrader. In MYD88-mutant diffuse large B cell lymphoma (DLBCL) models, KT-413 achieved superior tumor regression compared to existing therapies, such as IMiDs and selective IRAK4 targeting. The company plans to submit an Investigational New Drug Application (IND) and initiate a Phase 1 trial in the latter half of 2021, focusing on relapsed/refractory B cell lymphomas, particularly MYD88-mutant DLBCL, which represents a significant patient population.
Kymera Therapeutics (NASDAQ: KYMR) has announced the selection of a late-breaking abstract for presentation at the SID 2021 Annual Meeting from May 3-8, 2021. The abstract features new patient data related to hidradenitis suppurativa (HS) from a non-interventional study assessing IRAK4 expression and the effects of the IRAK4 degrader, KT-474. Presentation details include the title: Multiple mediators of inflammation correlate with IRAK4 expression in HS patients, scheduled for May 6, 2021, from 2:30 PM-4:00 PM ET.
Kymera Therapeutics (NASDAQ: KYMR) has appointed Elena Ridloff, CFA, to its Board of Directors, effective March 16, 2021. Ridloff will serve as Chair of the Audit Committee and brings over 20 years of biopharmaceutical experience, having held senior roles at commercial-stage firms and as an institutional investor. Kymera aims to leverage her expertise to advance its targeted protein degradation platform, focusing on innovative therapies for challenging diseases. Ridloff expressed excitement to contribute to Kymera's transformative year, as the company progresses three novel protein degrader programs into the clinic.